Secondary outcomes and efficacy analyses
co-infections, syphilis, chlamydia, gonorrhea, herpes simplex
CNS INFECTIONS, SYPHILIS, SECONDARY, BACTERIAL VAGINOSIS, TRICHOMONIASIS, GONORRHEA, HERPES SIMPLEX
In the planned secondary sensitivity analysis, including participants with type-specific HPV antibodies detected at enrollment, there were 88 incident-persistent infections in the HPV 16/18 mITT cohort: 1 in the nonavalent vaccine group, 3 among participants assigned to the bivalent group and 84 among those assigned to the control vaccine group (Table In the planned secondary extended-sensitivity analysis, excluding participants with HPV DNA detected at month 6, there were a total of 44 incident-persistent infections in the HPV 16/18 mITT cohort: 0 each among participants assigned to the bivalent and nonavalent vaccine groups and 44 among those assigned to the control vaccine group (Table In the planned secondary analyses to assess VE in the prespecified subgroups, as defined at enrollment, for the presence of co-infections (chlamydia, gonorrhea, herpes simplex type 2, trichomoniasis, syphilis and bacterial vaginosis), self-reported condom use, number of self-reported lifetime sex partners (1 versus 2+) and contraceptive method use, there was no difference in VE in predefined subgroups (Extended Data Tables 